CAR-T Therapy Shows Rapid Improvement in Severe Autoimmune Diseases

Recent developments in CAR-T-cell therapy have demonstrated rapid and substantial improvement in individuals with severe autoimmune diseases, according to published case reports and clinical studies.

One documented case involved a woman diagnosed with three life-threatening autoimmune conditions who experienced a marked recovery following CAR-T-cell therapy. Within weeks of receiving the treatment, she regained near-normal function and no longer required blood transfusions after just one week.

The therapy worked by targeting and removing malfunctioning B cells, which contributed to her autoimmune symptoms. Two weeks after treatment, she was able to resume normal daily activities, and subsequent monitoring showed that her returning B cells appeared healthy, suggesting a possible reset of her immune system.

Clinicians monitoring the patient noted that she continued to have low white blood cell counts and mildly elevated liver enzymes. These findings were attributed to previous long-term treatments, rather than the CAR-T therapy itself. The full details of this case were published in the medical journal Med.

What the numbers show

• In a study of 15 patients, a single CAR-T infusion led to symptom reduction or elimination, with no lupus relapses over up to two years
• The phase 1/2 CASTLE trial reported median B-cell depletion in 7 days and over 90% naïve B cells after reset
• High-grade leukopenia lasted a median of 14 days, and grade 4 lymphopenia lasted around 7 days after CAR-T infusion in the CASTLE trial

Beyond individual cases, CAR-T-cell therapy has been used in small groups of patients with autoimmune disorders such as lupus, systemic sclerosis, and idiopathic inflammatory myositis. These applications have shown reductions in symptoms and periods of remission, with some studies reporting no relapses in lupus patients during follow-up periods of up to two years.

The CASTLE basket trial, which included patients with three different autoimmune diseases, observed that CAR-T-cell therapy led to rapid depletion of B cells, typically within a week. After treatment, the majority of new B cells were naïve, indicating a reset of the immune system profile in these individuals.

Short-term side effects reported in clinical trials included temporary reductions in various white blood cell types, such as leukopenia and lymphopenia. These effects generally resolved within two weeks, according to trial data.

Research is ongoing to expand the use of engineered CAR-T therapies to a wider range of autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, multiple sclerosis, vasculitis, and others. Allogeneic anti-CD19 CAR-T cells have also been used in therapy-resistant cases, showing reductions in disease activity and sustained presence in the body with good tolerability.

Preclinical efforts are underway to develop CAR-T therapies that more selectively target disease-causing B cells while sparing healthy ones. For example, CART4-34 therapy is being developed for systemic lupus erythematosus and certain lymphomas, with phase I clinical trials planned as of early 2026.

* This article is based on publicly available information at the time of writing.